NCT03789682Completed
CD155 in Bladder Cancer
Predictive Value of CD155 for Survival and Effectiveness of Chemotherapy in Patients With Muscle Invasive Bladder Cancer
Source: ClinicalTrials.gov · Last updated 16 Apr 2025
Brief summary (registry, in English)
This research is designed to investigate the prognostic and predictive value of CD155 in muscle invasive bladder cancer.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 151 (actual)
- First submitted
- 27 Dec 2018
- Start date
- Jan 2018
- Primary completion date
- Jan 2023
- Lead sponsor
- Fudan University
- Diseases
- Bladder cancer
- NCT number
- NCT03789682
What you commit to
- Study type: Observational
- Participants enrolled: 151
- From Jan 2018 to the primary completion date, Jan 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- not enough tissue for immunohistochemistry
- patients with a second neoplasm
Who the study is looking for
- patients with non-metastatic muscle invasive bladder cancer
- pathology confirmed urothelial carcinoma
- underwent cystectomy and pelvic lymph node dissection
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fudan University Shanghai Cancer Center Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.